HK1206363A1 - μ-阿片受體肽的有益鹽 - Google Patents

μ-阿片受體肽的有益鹽

Info

Publication number
HK1206363A1
HK1206363A1 HK15106792.0A HK15106792A HK1206363A1 HK 1206363 A1 HK1206363 A1 HK 1206363A1 HK 15106792 A HK15106792 A HK 15106792A HK 1206363 A1 HK1206363 A1 HK 1206363A1
Authority
HK
Hong Kong
Prior art keywords
opiate receptor
receptor peptides
advantageous salts
salts
advantageous
Prior art date
Application number
HK15106792.0A
Other languages
English (en)
Inventor
Theodore Maione
Original Assignee
Cytogel Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogel Pharma Llc filed Critical Cytogel Pharma Llc
Publication of HK1206363A1 publication Critical patent/HK1206363A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK15106792.0A 2007-12-13 2015-07-16 μ-阿片受體肽的有益鹽 HK1206363A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US761707P 2007-12-13 2007-12-13

Publications (1)

Publication Number Publication Date
HK1206363A1 true HK1206363A1 (zh) 2016-01-08

Family

ID=40755912

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15106792.0A HK1206363A1 (zh) 2007-12-13 2015-07-16 μ-阿片受體肽的有益鹽

Country Status (8)

Country Link
US (6) US20110190214A1 (zh)
EP (2) EP2229400B1 (zh)
JP (1) JP5647002B2 (zh)
AU (1) AU2008334941B2 (zh)
CA (2) CA2984218C (zh)
ES (1) ES2550604T3 (zh)
HK (1) HK1206363A1 (zh)
WO (1) WO2009076672A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065648A1 (en) * 2009-09-15 2011-03-17 Maione Theodore E Advantageous mu-opiate receptor peptide compounds
EP2574172A4 (en) * 2010-05-21 2013-10-30 Cytogel Pharma Llc MATERIALS AND METHOD FOR TREATING INFLAMMATION
WO2013173730A2 (en) * 2012-05-18 2013-11-21 Cytogel Pharma, Llc. Novel therapeutic uses of mu-opiate receptor peptides
WO2018231838A1 (en) * 2017-06-12 2018-12-20 Board Of Regents Of The University Of Nebraska Hydrochloride salts of c5a receptor agonist peptides
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
AU2018368769B2 (en) * 2017-11-17 2024-05-09 Cytogel Pharma, Llc Polymer agonists of mu opioid receptors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US5885958A (en) * 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
JPH10330398A (ja) * 1997-05-28 1998-12-15 Asahi Glass Co Ltd 新規環状ペプチド
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
WO2002102833A1 (fr) * 2001-06-15 2002-12-27 Senju Pharmaceutical Co., Ltd. Nouveaux derives d'endomorphine
AU2002324133A1 (en) * 2001-09-03 2003-03-18 The University Of Bristol Inflammation modulatory compound comprising an endomorphin
CA2467555A1 (en) * 2001-11-29 2003-08-14 Schering Corporation Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl)-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-me thyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections

Also Published As

Publication number Publication date
EP2229400B1 (en) 2014-11-19
US20140142050A1 (en) 2014-05-22
US20220324908A1 (en) 2022-10-13
JP2011508727A (ja) 2011-03-17
AU2008334941A1 (en) 2009-06-18
EP2826786A1 (en) 2015-01-21
EP2229400A4 (en) 2012-01-04
US8940704B2 (en) 2015-01-27
AU2008334941B2 (en) 2013-02-14
US20110190214A1 (en) 2011-08-04
US20150152137A1 (en) 2015-06-04
CA2984218C (en) 2019-12-31
ES2550604T3 (es) 2015-11-11
US20180291060A1 (en) 2018-10-11
CA2984218A1 (en) 2009-06-18
WO2009076672A1 (en) 2009-06-18
EP2826786B1 (en) 2015-09-23
US20200339628A1 (en) 2020-10-29
JP5647002B2 (ja) 2014-12-24
CA2707733A1 (en) 2009-06-18
CA2707733C (en) 2018-01-02
EP2229400A1 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
EP2244575A4 (en) ANTAGONISTS OF THE ANGIOTENSIN II RECEPTOR
EP2242505A4 (en) GLYCOCONJUGATION OF POLYPEPTIDES USING OLIGOSACCHARYLTRANSFERASES
ZA201001597B (en) Octahydropentalene compounds as chemokine receptor antagonists
EP2427430A4 (en) 5-OXO-ETE RECEPTOR ANTAGONIST COMPOUNDS
HK1206363A1 (zh) μ-阿片受體肽的有益鹽
IL212551A0 (en) Cxcr4 receptor compounds
EP2034832A4 (en) IL-8 RECEPTOR ANTAGONIST
IL196587A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
HK1160642A1 (zh) 用作加壓素 受體拮抗劑的二氫四氮雜苯並薁的芳基環己基醚
IL217526A0 (en) Carbocyclic glyt1 receptor antagonists
GB0723712D0 (en) Peptides
IL216086A (en) Peptides that are ligands of somatostatin receptors
IL197979A0 (en) Method for peptide synthesis
EP2478001A4 (en) BENEFICIAL PEPTIDE COMPOUNDS OF MU OPIACEOUS RECEPTOR
EP2123666A4 (en) PEPTIDE
GB0724953D0 (en) Methods of peptide modification
IL193427A0 (en) Polypeptide antagonist
EP2250168A4 (en) ANTAGONISTS OF ANGIOTENSIN II RECEPTORS
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
EP2188305A4 (en) MODIFIED PEPTIDES HAVING TOXIN IMPROVING EFFECTS
GB0703945D0 (en) Peptide
EP2411813A4 (en) NEW RECEPTOR HETERO DIMERS / OLIGOMERS
EP2291076A4 (en) Angiotensin-II Receptor Antagonists
GB0812586D0 (en) Chimaeric peptide
ZA200810564B (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists